Bristol-Myers shares up after top investor resists Celgene deal


Bristol-Myers Squibb Co expressed disappointment on Thursday with the opposition of its top shareholder to a $74 billion takeover of Celgene Corp, and said it would press on with what would be the largest pharmaceutical acquisition of all time.